TABLE 1.
Isolate genotype (no. of isolates) | No. (%) of isolates with indicated imipenem MIC (μg/ml)b |
|||||||
---|---|---|---|---|---|---|---|---|
0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | >8 | |
All carbapenemase-positive isolates (1,493)a | 3 (0.2) | 10 (0.7) | 27 (1.8) | 101 (6.8) | 206 (13.8) | 206 (13.8) | 245 (16.4) | 695 (46.6) |
KPC (794) | 2 (0.3) | 16 (2.0) | 66 (8.3) | 103 (13.0) | 136 (17.1) | 471 (59.3) | ||
NDM (290) | 2 (0.7) | 28 (9.7) | 70 (24.1) | 190 (65.5) | ||||
OXA-48-like (300) | 2 (0.7) | 9 (3.0) | 22 (7.3) | 78 (26.0) | 106 (35.3) | 42 (14.0) | 18 (6.0) | 23 (7.7) |
VIM (92) | 3 (3.3) | 13 (14.1) | 27 (29.3) | 22 (23.9) | 27 (29.3) | |||
IMP (40) | 1 (2.5) | 1 (2.5) | 3 (7.5) | 3 (7.5) | 19 (47.5) | 7 (17.5) | 3 (7.5) | 3 (7.5) |
GES (3) | 2 (66.7) | 1 (33.3) |
The 1,493 carbapenemase-positive isolates included 1,485 isolates that were ertapenem nonsusceptible and 8 isolates that were ertapenem susceptible and phenotypically ESBL positive. Twenty-four isolates carried two carbapenemases: KPC plus VIM (KPC+VIM) (Greece, 3 isolates); KPC+NDM (Colombia, 1 isolate); KPC+OXA-48-like (Argentina, 1 isolate; Italy, 1 isolate; Morocco, 1 isolate); NDM+OXA-48-like (Egypt, 3 isolates; India, 1 isolate; Jordan, 1 isolate; Romania, 1 isolate; Serbia, 4 isolates; Tunisia, 1 isolate; United Arab Emirates, 2 isolates; Vietnam, 2 isolates); VIM+OXA-48-like (Croatia, 1 isolate; Turkey, 1 isolate). One isolate carried three carbapenemases: OXA-48-like+NDM+VIM (Turkey).
Imipenem MIC breakpoints: susceptible, ≤1μg/ml (gray shading); intermediate, 2 μg/ml; resistant, ≥4 μg/ml (11).